No connection

Search Results

ABBV vs AMN

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
AMN
AMN Healthcare Services, Inc.
BEARISH
Price
$20.49
Market Cap
$787.1M
Sector
Healthcare
AI Confidence
78%

Valuation

P/E Ratio
ABBV
163.63
AMN
--
Forward P/E
ABBV
15.42
AMN
30.31
P/B Ratio
ABBV
-146.66
AMN
1.22
P/S Ratio
ABBV
6.5
AMN
0.29
EV/EBITDA
ABBV
15.27
AMN
7.87

Profitability

Gross Margin
ABBV
71.46%
AMN
29.37%
Operating Margin
ABBV
35.5%
AMN
1.33%
Profit Margin
ABBV
4.0%
AMN
-10.14%
ROE
ABBV
137.96%
AMN
-35.9%
ROA
ABBV
9.59%
AMN
1.17%

Growth

Revenue Growth
ABBV
9.1%
AMN
-7.7%
Earnings Growth
ABBV
-88.7%
AMN
321.3%

Financial Health

Debt/Equity
ABBV
--
AMN
1.37
Current Ratio
ABBV
0.72
AMN
1.05
Quick Ratio
ABBV
0.47
AMN
0.94

Dividends

Dividend Yield
ABBV
3.05%
AMN
--
Payout Ratio
ABBV
490.15%
AMN
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
AMN BEARISH

The company exhibits severe financial distress with a Piotroski F-Score of just 2/9, indicating weak fundamental health. Despite recent earnings surprises and short-term EPS growth, the business is unprofitable (negative profit margin and ROE), leveraged (Debt/Equity of 1.37), and has declining revenues. Valuation metrics like a high Forward P/E of 30.31 and low Price/Sales of 0.29 reflect inconsistent pricing signals, while the stock has lost over 70% of its value in the past five years. The absence of an Altman Z-Score due to insufficient data further raises concerns about financial stability.

Strengths
Consistently beats earnings estimates with an average surprise of over 90% in the last four quarters
Recent quarterly EPS growth (Q/Q) of +30.0% shows potential operational improvement
Operating margin remains positive at 1.33% despite overall net losses
Risks
Piotroski F-Score of 2/9 signals severe financial weakness and high risk of continued deterioration
Negative profit margin (-10.14%) and ROE (-35.90%) indicate persistent unprofitability and poor capital efficiency
Revenue declining YoY by 7.70%, reflecting shrinking top-line and potential market share loss

Compare Another Pair

ABBV vs AMN: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and AMN Healthcare Services, Inc. (AMN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile